Founded in Basel, Switzerland (the global epicenter of pharmaceutical innovation), SunRegen Healthcare AG was established with a singular, unwavering mission.
SunRegen Healthcare AG was founded in Basel, Switzerland with one purpose: to discover and develop revolutionary therapies that protect and rescue neurons. Our executive leadership and scientific advisory boards are comprised of seasoned drug hunters, clinical development specialists, and business operators who have successfully navigated complex molecules from discovery through global commercialization at the world's leading pharmaceutical organizations, including Novartis, Roche, Alcon, and Allergan.
Beginning with the discovery of SBC003's neuroprotective mechanism in 2016, SunRegen has systematically built a platform validated across multiple animal models, recognized by elite innovation bodies including Johnson & Johnson's JLABS, the European Union's SME Instrument, and the Swiss Federal Innovation Agency (Innosuisse). Today, we are advancing SBC003 through CMC and GLP toxicology studies toward Phase I/II clinical trials, starting with Retinitis Pigmentosa and expanding into Dry AMD and broader CNS neurodegeneration.
Pipeline Programs
Active indications
Innovation Grant
Innosuisse funding
Awards & Recognition
International honors
Years Expertise
Core Team average
RP Patients Worldwide
Inherited retinal dystrophy
Projected AMD by 2040
WHO global projection
Patients Globally
Affected by Neurodegenerative Diseases
A future where neurodegeneration is treatable, not terminal — where a daily oral pill halts apoptosis, clears toxic protein aggregates, and restores function across retinal and central nervous system disease.
To develop first-in-class oral neuroprotective therapies that target the neuroglobin pathway and restore cellular proteostasis. We start with the most underserved retinal indications — Retinitis Pigmentosa and Dry AMD — then extend the same mechanism to Alzheimer's, Parkinson's, and ALS.
What we stand for
Six principles guide every decision SunRegen makes — from how we run a preclinical experiment to how we structure a partnership.
Click through the stack to explore each one.
CEO & Managing Director
CEO & Managing Director
David holds a Master's degree in Electrical Engineering and brings a decade of senior management experience with multinational technology conglomerates including Honeywell and HP to the table. As an entrepreneur, he has a proven track record in international capital raising and cross-cultural team leadership, having successfully navigated SunRegen through multiple funding rounds and strategic corporate partnerships across Switzerland, Asia, and North America.
Founder, CSO & Chairman
Founder, CSO & Chairman
Dr. Dong holds both a Medical Degree and a Ph.D. in infectious disease from Beijing University and brings over 20 years of expertise in drug research and development across pharma and academia. A former Senior Medical Scientific Expert at Novartis Basel Headquarters, she is a four-time Novartis Award recipient with 30+ peer-reviewed publications. The discoverer of SBC003's neuroprotective mechanism, she pioneered SunRegen's phenotype-to-pathway reverse-engineering approach to drug discovery.
Board Member
Board Member
Dr. Chiho "Hubert" Wong is a registered general practitioner in both Hong Kong and mainland China. He holds a Master of Philosophy in Surgical Sciences and a Master of Science in Health Service Management from the Chinese University of Hong Kong. A dual fellow of the Hong Kong College of Health Service Executives and the Australian College of Healthcare Management, he brings extensive expertise to healthcare leadership.
Our leadership and scientific advisory team represent decades of hard-won drug development expertise across the world's most prestigious pharmaceutical organizations. The executive team has proven experience navigating molecules through preclinical, IND, and clinical development. Our scientific advisory board includes a former VP & Global Head of Preclinical Safety at Novartis (40+ new drug registrations), the former Head of Retina Discovery at Allergan and VP of Retinal R&D at Alcon, a former leading Alzheimer's neuroscience researcher at Novartis recognized as an Outstanding Scientist, and a Principal Scientist at the Schepens Eye Research Institute / Harvard Medical School. This institutional pedigree directly de-risks the SBC003 development pathway.
DMPK and Toxicology Lead
40+ years in drug metabolism, toxicology, and preclinical safety. Former VP & Global Head of Preclinical Safety at Novartis, instrumental in managing over 40 successful new drug registrations across oncology, CNS, and respiratory indications.
Ophth Drug Development Expert
30+ years overseeing flagship ophthalmology therapy development. Former Head of Retina Discovery at Allergan and VP of Retinal R&D at Alcon. Expert in age-related macular degeneration and geographic atrophy therapeutic development.
Head of R&D
35+ years in clinical pharmacology, rigorous pharmacovigilance, and drug safety operations. Former expert at Novartis Pharma AG and Sandoz, leading projects spanning Good Laboratory Practice (GLP) safety studies and global drug registration affairs.
Neurological Strategic Development Lead
24+ years in leading positions at Novartis and Sandoz Preclinical Neuroscience Research. Recognized as an Outstanding Scientist at Novartis for pivotal contributions to Alzheimer's disease drug development. Co-author of 200+ peer-reviewed publications.
Head of R&D
Principal Scientist at the Schepens Eye Research Institute of Mass. Eye and Ear, and Instructor in Ophthalmology at Harvard Medical School. Leading expert in mechanisms of retinal degeneration and regeneration, including glaucoma and Retinitis Pigmentosa.
DMPK and Toxicology Lead
40+ years in drug metabolism, toxicology, and preclinical safety. Former VP & Global Head of Preclinical Safety at Novartis, instrumental in managing over 40 successful new drug registrations across oncology, CNS, and respiratory indications.
Ophth Drug Development Expert
30+ years overseeing flagship ophthalmology therapy development. Former Head of Retina Discovery at Allergan and VP of Retinal R&D at Alcon. Expert in age-related macular degeneration and geographic atrophy therapeutic development.
Head of R&D
35+ years in clinical pharmacology, rigorous pharmacovigilance, and drug safety operations. Former expert at Novartis Pharma AG and Sandoz, leading projects spanning Good Laboratory Practice (GLP) safety studies and global drug registration affairs.
Neurological Strategic Development Lead
24+ years in leading positions at Novartis and Sandoz Preclinical Neuroscience Research. Recognized as an Outstanding Scientist at Novartis for pivotal contributions to Alzheimer's disease drug development. Co-author of 200+ peer-reviewed publications.
Head of R&D
Principal Scientist at the Schepens Eye Research Institute of Mass. Eye and Ear, and Instructor in Ophthalmology at Harvard Medical School. Leading expert in mechanisms of retinal degeneration and regeneration, including glaucoma and Retinitis Pigmentosa.
DMPK and Toxicology Lead
40+ years in drug metabolism, toxicology, and preclinical safety. Former VP & Global Head of Preclinical Safety at Novartis, instrumental in managing over 40 successful new drug registrations across oncology, CNS, and respiratory indications.
Ophth Drug Development Expert
30+ years overseeing flagship ophthalmology therapy development. Former Head of Retina Discovery at Allergan and VP of Retinal R&D at Alcon. Expert in age-related macular degeneration and geographic atrophy therapeutic development.
Head of R&D
35+ years in clinical pharmacology, rigorous pharmacovigilance, and drug safety operations. Former expert at Novartis Pharma AG and Sandoz, leading projects spanning Good Laboratory Practice (GLP) safety studies and global drug registration affairs.
Neurological Strategic Development Lead
24+ years in leading positions at Novartis and Sandoz Preclinical Neuroscience Research. Recognized as an Outstanding Scientist at Novartis for pivotal contributions to Alzheimer's disease drug development. Co-author of 200+ peer-reviewed publications.
Head of R&D
Principal Scientist at the Schepens Eye Research Institute of Mass. Eye and Ear, and Instructor in Ophthalmology at Harvard Medical School. Leading expert in mechanisms of retinal degeneration and regeneration, including glaucoma and Retinitis Pigmentosa.
From Basel incubators to global pharma — a track record of independent validation across our journey.
Awarded a second Innosuisse grant by the Swiss Federal Innovation Agency in 2026
Enrolled into JLABS Shanghai by J&J in 2023
Seal of Excellence SME Instrument of EU Horizontal 2020 Program in 2018-2019
Winner of the Startup Slam Competition at the 2018 BIO-Europe
Winner of IMAGINE IF Global Top 20 Finalists in 2017
Enrolled Into BaseLaunch, A Top Swiss BioIncubator in 2017
Coaching Program by Innosuisse, A Swiss Federal Innovation Agency
Awarded a second Innosuisse grant by the Swiss Federal Innovation Agency in 2026
Enrolled into JLABS Shanghai by J&J in 2023
Seal of Excellence SME Instrument of EU Horizontal 2020 Program in 2018-2019
Winner of the Startup Slam Competition at the 2018 BIO-Europe
Winner of IMAGINE IF Global Top 20 Finalists in 2017
Enrolled Into BaseLaunch, A Top Swiss BioIncubator in 2017
Coaching Program by Innosuisse, A Swiss Federal Innovation Agency
We welcome experienced scientists from the CNS and retinal field, or industry experts for preclinical/clinical development, to contact us. Please send your CV and cover letter to [email protected].
Pioneering first-in-class orally bioavailable compounds to halt neurodegeneration and restore vision. Clinical-stage. Basel, Switzerland.
© 2026 SunRegen Healthcare AG. All rights reserved.
Robinienweg 51, 4153 Reinach, Switzerland
UID: CHE-295.245.274
This website contains forward-looking statements regarding future products, development plans, and business strategies. Actual results may differ materially. Nothing on this site constitutes medical or investment advice.